NOTUM is a potential pharmacodynamic biomarker of Wnt pathway inhibition.

Journal Article (Journal Article)

Activation of Wnt signaling due to Wnt overexpression or mutations of Wnt pathway components is associated with various cancers. Blocking Wnt secretion by inhibiting PORCN enzymatic activity has shown efficacy in a subset of cancers with elevated Wnt signaling. Predicting response to upstream Wnt inhibitors and monitoring response to therapeutics is challenging due to the paucity of well-defined biomarkers. In this study we identify Notum as a potential biomarker for Wnt driven cancers and show that coordinate regulation of NOTUM and AXIN2 expression may be a useful predictor of response to PORCN inhibitors. Most importantly, as NOTUM is a secreted protein and its levels in blood correlate with tumor growth, it has potential as a pharmacodynamic biomarker for PORCN and other Wnt pathway inhibitors.

Full Text

Duke Authors

Cited Authors

  • Madan, B; Ke, Z; Lei, ZD; Oliver, FA; Oshima, M; Lee, MA; Rozen, S; Virshup, DM

Published Date

  • March 15, 2016

Published In

Volume / Issue

  • 7 / 11

Start / End Page

  • 12386 - 12392

PubMed ID

  • 26848981

Pubmed Central ID

  • PMC4914292

Electronic International Standard Serial Number (EISSN)

  • 1949-2553

Digital Object Identifier (DOI)

  • 10.18632/oncotarget.7157


  • eng

Conference Location

  • United States